This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

H.C. Wainwright Keeps Their Buy Rating on enGene Holdings (ENGN)

Tipranks - Tipranks - Thu Apr 30, 11:08AM CDT

In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on enGene Holdings, with a price target of $25.00.

Claim 55% Off TipRanks

According to TipRanks, Y. Maldonado is a 5-star analyst with an average return of 41.4% and a 56.89% success rate. Y. Maldonado covers the Healthcare sector, focusing on stocks such as ImmunityBio, Protara Therapeutics, and Verastem.

enGene Holdings has an analyst consensus of Strong Buy, with a price target consensus of $23.64.

See the top stocks recommended by analysts >>

Based on enGene Holdings’ latest earnings release for the quarter ending January 31, the company reported a quarterly GAAP net loss of $29.75 million. In comparison, last year the company had a GAAP net loss of $24.62 million

Read More on ENGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).